Topical pimecrolimus for paediatric cutaneous mastocytosis. Mashiah J et al. Clin Exp Dermatol. 2018 Feb 20.

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis. Scheeweiss M et al. Haematologica. 2018 Feb 8. 

A "foamy" mastocytosis case. Kim et al. Blood. 2018 Feb 1.

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells. MedPeter B et al. Leukemia. 2018 Apr.

Midostaurin: a magic bullet that blocks mast cell expansion and activation. Valent P et al. Ann Oncol. 2017 Oct 1;28(10):2367-2376

Prevalence and risk factors for fragility fracture in systemic mastocytosis. Degboé Y et al. Bone. 2017 Sep 14;105:219-225.

Neuroimaging evidence of brain abnormalities in mastocytosis. Boddaert N et al. Transl Psychiatry. 2017 Aug 8;7(8):e1197

Targeted Treatment Options in Mastocytosis. Vaes M et al. Front Med (Lausanne). 2017 Jul 20;4:110.

Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology.
A French National Survey on Clotting Disorders in Mastocytosis.
Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis.
Current treatment options in patients with mastocytosis: status in 2015 and future perspectives.
Isolated flushes without permanent, fixed or other skin lesions in patients with systemic mastocytosis: a case series of 9 patients.
Decreased tryptophan and increased kynurenine levels in mastocytosis associated with digestive symptoms.
Mast cells' involvement in inflammation pathways linked to depression: evidence in mastocytosis.
FDG-PET/CT findings in systemic mastocytosis: a French multicentre study.